Compare · ALZN vs CGTX

ALZN vs CGTX

Side-by-side comparison of Alzamend Neuro Inc. (ALZN) and Cognition Therapeutics Inc. (CGTX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. ALZN focuses on Biotechnology: Pharmaceutical Preparations, while CGTX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
  • CGTX is the larger of the two at $60.8M, about 10.7x ALZN ($5.7M).
  • CGTX has been more active in the news (5 items in the past 4 weeks vs 1 for ALZN).
  • CGTX has more recent analyst coverage (4 ratings vs 1 for ALZN).
MetricALZNCGTX
Company
Alzamend Neuro Inc.
Cognition Therapeutics Inc.
Price
-
-
Market cap
$5.7M
$60.8M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2021
2021
News (4w)
1
5
Recent ratings
1
4
ALZN

Alzamend Neuro Inc.

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

CGTX

Cognition Therapeutics Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Latest ALZN

Latest CGTX